Encompass Health Corporation (EHC) Hit a 52 Week High, Can the Run Continue?
Encompass Health (EHC) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.
Zacks·10h ago
More News
Encompass Health (EHC) Up 8.6% Since Last Earnings Report: Can It Continue?
Encompass Health (EHC) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Zacks·6d ago
Is it Time to Hold on to Community Health Systems Stock?
CYH benefits from rising occupancy, higher revenue per admission, and business streamlining, supporting its case as a stock to retain in your portfolio.
Zacks·11d ago
Why Encompass Health (EHC) is a Top Growth Stock for the Long-Term
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Zacks·11d ago
Why Encompass Health (EHC) is a Top Value Stock for the Long-Term
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Zacks·14d ago
Is Encompass Health (EHC) Stock Outpacing Its Medical Peers This Year?
Here is how Encompass Health (EHC) and Idexx Laboratories (IDXX) have performed compared to their sector so far this year.
Zacks·14d ago
Aveanna Healthcare Holdings Inc. (AVAH) Hit a 52 Week High, Can the Run Continue?
Aveanna (AVAH) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.
Zacks·15d ago
NVNO's Shares Decline on Unfavorable FDA Review Outcome for VenoValve
enVVeno Medical shares plunge after the FDA rejects its VenoValve PMA, citing insufficient trial data and safety concerns tied to the surgical procedure.
Zacks·15d ago
NVCR Stock Slips Despite PMA Application to Treat Pancreatic Cancer
NovoCure submits a PMA to the FDA for TTFields therapy in pancreatic cancer, aiming to expand its oncology reach.
Zacks·18d ago
Encompass Health Corporation (EHC) Hits Fresh High: Is There Still Room to Run?
Encompass Health (EHC) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.